Faricimab (Vabysmo)

Canada’s Drug Agency (CDA-AMC) recommends that Vabysmo be reimbursed by public drug plans for the treatment of macular edema secondary to retinal vein occlusion (RVO) if certain conditions are met. Vabysmo should be covered to treat patients with macular edema secondary to RVO provided that it is covered for a similar patient population to other anti–vascular endothelial growth factor (VEGF) drugs currently reimbursed by public drug plans for the treatment of patients with macular edema secondary to RVO. Vabysmo should only be reimbursed in a similar way to other anti-VEGF drugs currently reimbursed by public drug plans for the treatment of patients with macular edema secondary to RVO and the cost of Vabysmo should not exceed the drug program cost of treatment with other anti-VEGFs reimbursed for macular edema secondary to RVO.